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Abstract
The incidence of ovarian cancer in the UK has increased by almost twenty percent since the 1970’s and the majority of cases are not 
diagnosed until the late stages, when metastasis is more likely to have occurred. Focal Adhesion Kinase (FAK) is one of the key protein 
complexes which is integral to cell migration and has been linked to a variety of solid tumours. ShenLingLan (SLDM) is a traditional herbal 
medicine which has been formulated for the treatment of solid tumours. This study aimed to establish the impact of SLDM on FAK in 
ovarian cancer cells in vitro and transcript levels of FAK in an ovarian cancer cohort. FAK and paxillin phosphorylation events stimulated by 
SLDM treatment were identified using a KinexusTM antibody based protein array. The impact of SLDM on cell attachment and migration was 
evaluated using Electric cell-substrate impedance sensing (ECIS), whilst the changes in focal adhesion complex localisation were assessed 
using immunofluorescence. In an ovarian cancer cohort, differences in FAK and paxillin transcript levels were assessed against key clinical 
parameters such as differentiation, stage and survival outcome. SLDM treatment of ovarian cancer cells in vitro resulted in the suppression 
of FAK and paxillin phosphorylation at several sites, which appeared to manifest as decreased cellular attachment and migration in a range 
of immortalised ovarian cancer cells. Increased FAK and paxillin transcript copies were observed in high grade and poorly differentiated 
ovarian tumours as well as in tumours from patients with ovarian cancer related incidence. SLDM has a profound effect on the migratory 
and adhesive properties of ovarian cancer cells, potentially via inhibitory effects on the activation of the FAK pathway, which is aberrant 
in clinical ovarian cancers. 
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Introduction
Cell-matrix adhesion is central to a number of cellular 
events during cancer development, in particular cell 
migration and the metastatic spread of cancer cells [1]. 
Via a range of stimuli, integrins and transmembrane 
proteins, within normal and malignant cells, interact with 
extracellular matrix (ECM) proteins and result in cellular 
movement, as well as other cellular functions [2]. Within 
cells, integrins are also linked to cytoskeletal proteins 
which, through phosphorylation events, have the ability to 
assemble and disassemble focal adhesion complexes [3]. 
Alterations in these pivotal and dynamic interactions have 
been identified as key events in the ability of a range of 
cancer cells to adhere to and disassociate from the ECM, 
at the primary and secondary sites, essential traits in 
cellular migration and invasion ultimately contributing to 
metastatic spread [4, 5].
 
Ovarian cancer annually affects nearly 25% of the world’s 
female population and is responsible for 140,000 deaths 
every year [6]. Still renowned for its poor survival rates, the 
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worst of all female cancers, the five year survival rate for 
ovarian cancer patients remains under fifty percent. This 
poor survival is in part due to the late stages of diagnosis 
(III and IV) in which up to twenty per cent of patients 
already have metastatic spread [7]. Evidence suggests that 
it is tumour recurrence and metastatic spread which are 
responsible for ovarian cancer related deaths. 
Focal Adhesion Kinase (FAK) is a central component within 
the complexities of matrix-cell interactions. Within the last 
decade FAK and certain members of the focal adhesion 
complex proteins (paxillin, alpha-actinin, talin and vinculin) 
have been found to have aberrant expression levels and/
or levels of activation and thus validated as therapeutic 
targets, as well as disease progression and prognostic 
markers in certain solid cancers [8-11]. We have previously 
reported that a traditional Chinese medicine formula, 
YangZheng XiaoJi (YZXJ) is able to markedly suppress the 
phosphorylation levels of FAK in cancer cells and indeed 
in vascular endothelial cells [12, 13]. The consequences 
of blocking FAK using this medicine is of dual benefit, 
namely the reduction of tumour cell migration as well as 
the reduction of angiogenesis, which collectively resulted 
in slower in vivo tumour growth [12, 14-16].
 
Other kinase pathways, including suppressor of cytokine 
signalling (SOCS), mitogen activated protein kinases (MAPK) 
and integrin linked kinase (ILK), lead to transcriptional 
regulation, resulting in gene expression changes which 
also participate in the regulation of migration, adhesion 
and proliferation of cells. A number of specific and non-
specific compounds, some of which have already found 
their way to the clinics as cancer therapeutic agents, have 
been shown to be able to suppress the activation of FAK, 
and hence the motile and aggressive nature of cancer cells 
[8]. On this basis, we investigated another formulation, 
ShenLingLan (SLDM), which was modified based on YZXJ, by 
removal of two ingredients in order to improve the efficacy 
of the formulation. There are promising early clinical signs 
that this medicine benefits a variety of cancer patients 
[17, 18]. Currently, SLDM is used as a formulated capsule, 
particularly for those who are receiving chemotherapy. It 
has been demonstrated that the medicine is safe in clinical 
trials and was able to influence T-cell functions [19]. We 
have recently reported that the medicine was able to 
influence the GSK-3 signalling pathways in ovarian cancer 
cells [20, 21].
The present study aimed to investigate if, and subsequently 
how, the medicine may work using a series of methods, 
in a hope to find and eventually provide scientific support 
for using this medicine in patients. We primarily focused 
on the action of SLDM on FAK, FAK- mediated cell-
matrix adhesion and cellular migration. We particularly 
concentrated on the effect of the medicine on FAK and 
members of the focal adhesion complex and indeed the 
immediate downstream kinases in ovarian cancer cells, a 
highly aggressive tumour type that has a strong link to FAK 
activation. We also investigated the expression of FAK and 
paxillin in a cohort of human ovarian tumours. SLDM had 
a profound effect on FAK and its downstream signalling 
events, leading to suppression of cell-matrix adhesion and 
cellular migration of ovarian cancer cells.
 
Material and methods
Materials and cells
Two ovarian cell lines, SKOV-3 and COV-504, were 
purchased from LGC Standard/ ATCC (Southampton, 
England, UK). Both cell lines were cultured in Dulbecco’s 
modified eagle medium (DMEM) (Sigma Aldrich, Dorset, UK) 
supplemented with 10% foetal calf serum (12133C, Sigma 
Aldrich, Dorset, UK) and antibiotic antimycotic solution 
(A5955, Sigma Aldrich, Dorset, UK) in an incubator pre-set 
to 37oC and 5% carbon dioxide. PF573228, a small inhibitor 
for FAK was purchased from Tocris (Bristol, England, UK). 
Human paxillin antibody (BD610051) was purchased from 
BD Transduction laboratories (Oxford, England, UK). FITC-
conjugated secondary antibody (F5262) was purchased 
from Sigma Aldrich (Dorset, UK).
Tumour samples
Ovarian tumours (n = 52) were collected with patient 
consent immediately after surgery and stored at -80oC until 
use. Key clinical and pathological information, including 
tumour staging, differentiation and outcome were also 
obtained from the clinical database (Table 1). The age of 
patients ranged from 36 to 73 years of age. 
Table 1 The clinical and pathological information of the cohort.
Clinical information Patient numbers (n)
Stage
 1/2 7
 3/4 45
Differentiation
Low/non 38
Moderate 8
High 6
Incidence
Incidence free 25
With incidence 27
Survival
Alive 36
Died 16
ShenLingLan extract (SLDM)
Fourteen medicinal herbs (including Astragalus, Ligustrum 
lucidum, ginseng, Ganoderma lucidum, Curcuma, 
Gynostemma, Atractylodes (fried), Poria, Cordyceps 
sinensis, Xu Changqing, Eupolyphaga, Panax, diffusa, 
Scutellaria barbata, The Divine Comedy (fried)) have been 
combined by Yiling Pharmaceuticals (Shijiazhuang, Hebei, 
China) to form ShenLingLan. Using a DMSO based method 
[13] a SLDM extract was prepared from ShenLingLan. In 
brief, ShenLingLan formulated powder was combined with 
DMSO in a fixed weight/volume ratio before the mixture 
was agitated on a rotating wheel (at 100rpm) (Labinco 
BV, Wolf Laboratory, York, England, UK) for 12 h at 4oC. 
Subsequently the mixture was centrifuged at 15,000 × 
g, for 20 min at 4oC. From the fractionated mixture the 
clear supernatant was collected, pooled and filtered using 
filtration filters (pore size 0.20 µm, Sartorius Stedim, 
Sartorius, Epson, Surrey, UK). This pooled concentrated 
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extract was diluted in a balanced salt solution (BSS) and 
standardised using the extract’s optical density, calculated 
with a spectrophotometer set at a wavelength of 450 nm 
(Biotek, Wolf Laboratory). A master preparation which 
gave 0.25 OD at 450 nm was stored as the master stock 
and named SLDM for all subsequent experiments. 
Immunofluorescent staining
Ovarian cancer cells (3-4 x 104/well) were seeded into 8-well 
Millicell EZ glass slides (Merck Millipore, Cork, Ireland) and 
left to settle overnight before being treated with SLDM for 
two hours. Slides were fixed using ice cold ethanol for 30 
min prior to being washed with Tris buffered saline (TBS) (25 
mM, pH 8.4). Subsequently cells were lightly permeabilised 
with 0.1% Triton X100 for 3 min. After thorough washing, 
slides were blocked with TBS which contained 7.5% goat 
serum for at least two hours. Primary paxillin antibody was 
diluted in the blocking buffer and added to the chamber 
slides which were left to incubate overnight at 4oC. Prior to 
FITC- tagged secondary antibody (1:250) being added for 
one hour, slides were washed with TBS. Slides were further 
washed and mounted using FluorSaveTM (Calbiochem, 
Nottingham, England, UK). Images were captured using an 
Olympus microscope and a Hamamatsu digital camera.
Protein array
Ovarian cancer cells were cultured to 90% confluence in 
two T75 tissue culture flasks, medium was removed and 
the cells washed with TBS buffer before being replaced 
with DMEM supplemented with 5% FCS. After five hours, 
SLDM treatment was prepared in DMEM supplemented 
with 5% FCS and added to the cells. After five hours the 
ovarian cancer cells were scraped from the flasks and 
pelleted by centrifugation at 2,500rpm for 5 min. Lysis 
buffer was added to the cell pellets and samples placed on 
a rotating wheel for one hour at 4oC. This was followed by 
the lysate samples being centrifuged at 12,000 g for 10 min 
at 4oC. After centrifugation supernatants from the samples 
were collected and quantified based on absorbance prior 
to being adjusted to 2 mg/ml and stored at -20oC until 
further use. KAM850 antibody based protein arrays, which 
capture 854 antibodies spotted on array slides (Kinexus 
Bioinformatics Ltd, Vancouver, Canada) were used during 
the course of this study. The following key parameters 
were collected and used for the subsequent data analyses: 
Globally Normalized Signal Intensity - globally normalized 
background corrected intensity values were calculated by 
combining all the intensities from the net signal median 
values for each sample. Z Scores - Z score transformation 
corrected data internally within a single sample. Z Score 
difference - The difference between the observed protein 
Z scores in samples for comparison. Z Ratios - Divide the Z 
score differences by the SD of all the differences for each 
comparison.
Electric cell-substrate impedance sensing (ECIS)
This method was used to analyse ovarian cell adhesion and 
cell migration. Briefly, 96-well W96E1 microarrays were 
used on an ECIS Ztheta instrument (Applied Biophysics 
Ltd, Troy, New Jersey, USA) set up in a pre-set incubator 
(37oC and 5% carbon dioxide). Ovarian cancer cells were 
added to an array in triplicate and once attached to the 
instrument were immediately tracked by the software 
over a range of frequencies (1,000 Hz to 64,000 Hz) using 
automated gold electrodes. To model cellular migration, 
once the electronic traces had plateaued indicating a 
complete monolayer had been formed, an electrical 
wounding (2,000 mA for 20 sec each) was applied through 
the gold modules creating artificial wounds. Cells were 
again immediately tracked as they migrated back over the 
gold electrodes. Both the adhesion and migration were 
analysed using the mathematical modelling methods as 
previously described [20, 21].
 
Quantitative analysis of FAK and paxillin transcripts in tumour 
samples
Transcript levels of both FAK and paxillin were quantitatively 
determined using real-time quantitative PCR performed 
on Applied Biosicence StepOne Plus (Paisley, England, 
UK). The quantitative detection was based on a modified 
Amplifluor™ probe method previously reported [20, 21]. 
Primer details are given in Table 2 including the internal 
house-keeping control cytokeratin-19 (CK-19) and levels 
of FAK and paxillin transcripts were generated using an 
internal standard (PDPL), of known copy number, which 
was simultaneously amplified with the tumour samples. 
The reaction conditions were as follows: 94oC for 5 min, 96 
cycles at 94oC for 15 sec, 55oC for 35 sec and 72oC for 20 
sec. The results are shown in two ways: levels of transcripts 
based on equivalent amounts of mRNA, and as a target: 
CK-19 ratio [22]. 
Table 2 Primer sequences for quantitative PCR
Primer name Sense Anti-sense
FAK CTATCCAGGTCAGGCATCT ACTGAACCTGACCGTACAC 
GCAGGTCCAATACTGTAGA
Paxillin ACAGTCGCCAAAGGAGTC ACTGAACCTGACCGTACAA 
GTGGGTGCAGACGAAGT
CK-19 AGCCACTACTACACGACCAT ACTGAACCTGACCGTACAT 
CGATCTGCAGGACAATC
PDPL GAATCATCGTTGTGGTTATG ACTGAACCTGACCGTACAC 
TTTCATTTGCCTATCACAT
* ACTGAACCTGACCGTACA – Z sequence for uniprimer probe.
Statistical analysis
Minitab (Minitab Ltd, Coventry, UK) statistical software 
package (version 14) was used to perform statistical 
analysis on tumour RNA samples. Data which was normally 
distributed was assessed using the two-sample t-test, 
whilst non-normally distributed data was assessed using 
the Mann-Whitney test. Z score was applied to the Kinexus 
data where a score of 1.64 or -1.64 was p = 0.05. 
Results
ShenLingLan showed inhibitory effects on the phosphorylation 
of FAK, paxillin and the downstream signalling events in 
ovarian cancer cells
The Kinexus protein array identified a range of 
phosphorylation sites in which activity was decreased 
after SKOV-3 ovarian cancer cells had been treated 
with SLDM (Figure 1). Though there appeared to be 
little change detected in the pan-specific FAK antibody, 
dramatic decreases in phosphorylation were detected at 
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serine-910 (S-910), tyrosine-397 (Y-397) and the combined 
sites of tyrosine-576 and -577 (Y-576 + Y-577) compared 
to the untreated control (Figure 1a). Phosphorylation of 
paxillin was also decreased in SKOV-3 cells with the most 
noticeable decrease being observed in the pan-specific 
antibody compared to the untreated control (Figure 1b). 
Small decreases in tyrosine-119 (Y-119) and tyrosine-31 
(Y-31) phosphorylation were also detected by the Kinexus 
protein array. Subsequent downstream tyrosine kinase 
targets for FAK and paxillin were also included in the array 
(Figure 1c). Of the FAK downstream events, pan-specific 
Csk and Shc1 tyrosine-349 (Y-349) and tyrosine-350 
(Y-349 + Y-350) phosphorylation events were decreased in 
SKOV-3 treated cells compared to the untreated control. 
Treatment of SKOV-3 cells with SLDM appeared to increase 
the phosphorylation of Rac1, though the activity at serine-
71 (S-71) appeared to be reduced compared to the 
untreated control. No significant changes were detected 
by the pan-specific Src antibody, however a slight increase 
was detected at Src tyrosine-419. Detection levels of ILK1 
and Fyn, a member of the Src family of kinases, showed 
little difference between the treated and control cells. 
Figure 1 Phosphorylation changes in FAK, paxillin and downstream molecules in SKOV-3 cells after treatment with SLDM.
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Signal strength, indicative of expression for pan-specific 
FAK and specific serine and tyrosine sites with FAK, were 
screened in SKOV-3 ovarian cancer cells after treatment 
with SLDM (a). Changes in phosphorylation state was seen at 
serine-910 (S-910), tyrosine-397 (Y-397) and a combination 
of tyrosine-576 and 577 (Y-576 + -577) compared to the 
untreated control, duplication represents use of different 
antibodies to probe the same phosphorylation site present 
on the same chip. Reductions in signal strength were also 
detected at all three of the paxillin sites detected compared 
to the untreated control (b). Downstream protein kinases 
were also screened on the antibody array (c). Reductions 
in signal strength were seen in Csk1 and Shc1, whilst an 
increase was seen in Rac1. No obvious detection changes 
were seen in ILK1 and Fyn. Signal strength changes are 
represented by the green bars for the untreated control 
and purple bars for the SLDM treated cells. Z-ratio is 
represented by the blue bar in which the middle is zero 
and the increase or decrease is represented by the 
directional change. Average measurement of duplicates 
shown. Z-ratio >1.64 was considered significant.
ShenLingLan treatment affects paxillin localisation in ovarian 
cancer cells
Immunofluorescence staining was used to explore the 
changes in paxillin detected by the Kinexus array, and 
explore any potential localisation changes which might 
occur in the ovarian cancer cells (Figure 2). In the untreated 
SKOV-3 (top panel) cells paxillin appears to be diffuse in the 
cytoplasm, with some small amounts clustered at the cell 
membrane potentially indicating focal adhesion clusters 
(indicated by white arrows). After treatment with SLDM 
the clusters appear to become more prominent at the cell 
membrane (white arrows, top right panel). In contrast, in 
the untreated COV-504 (bottom panel) ovarian cancer cells 
intense clusters of paxillin staining are clear (white arrows) 
and appear to be potentially organised along the actin 
cytoskeleton (bottom left pane, red arrows). COV-504 cells 
treated with SLDM appear to show a reduced number of 
these intense paxillin clusters (white arrows, bottom right 
panel) with some cells demonstrating diffuse cytoplasmic 
staining (red arrows). 
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Paxillin staining of SKOV-3 cells (top panel) and COV-504 
cells (bottom panel). In the untreated SKOV-3 cells (top left 
panel) paxillin staining generally appears to be diffuse in 
the cytoplasm with some small clusters (indicated by white 
arrows) appearing at the cell membrane. In SKOV-3 cells 
treated with SLDM (top right panel) in some of the cells 
staining appears to have clustered, potentially indicating 
focal adhesion complexes, at the cell membranes (white 
arrows). Within the control COV-504 cells paxillin staining 
indicative of focal adhesion clusters appeared through 
the cells (white arrows) and also appeared to align along 
the actin cytoskeleton (red arrows, bottom left panel). 
Treatment of COV-504 ovarian cancer cells with SLDM 
resulted in disruption and reduction of the paxillin stained 
clusters at the leading edges of the cells indicative of loss 
of focal adhesion clusters (white arrows, top and bottom 
right panels) with the staining appearing diffuse in the 
cytoplasm (red arrows, bottom right panel).
ShenLinLan resulted in a concentration dependent inhibition 
of cell adhesion and migration alone and in combination with 
an FAK inhibitor
Using an ECIS based method, we tested the potential effects 
of SLDM on ovarian cancer cell adhesion and migration. 
Previous work has demonstrated that SLDM does not 
have a toxic effect on ovarian cancer cells in vitro [20, 21]. 
ECIS modelling was used to qualitatively examine ovarian 
cancer cell adhesion and migration. SLDM inhibited ovarian 
cancer cell attachment and migration in a concentration 
dependent manner (Figure 3). Treating SKOV-3 or COV-504 
cells with an FAK small inhibitor, PF537228 also appeared 
to result in a decrease in cellular attachment and migration. 
The combination treatment of increasing concentrations 
of SLDM and PF537228 resulted in a further decrease in 
ovarian cancer cell attachment and migration.
Qualitatively analysed, using ECIS modelling, treatment 
of COV-504 and SKOV-3 ovarian cancer cells with SLDM 
decreased their cell attachment (top panels) and cellular 
migration (bottom panels) as we previously reported 
[20]. This concentration dependent inhibition of cellular 
attachment (top panels) and migration (bottom panels) was 
further inhibited when ovarian cancer cells were treated 
with a combination of increasing SLDM concentrations 
and an FAK small inhibitor PF537228.
Human ovarian tumours had highly expressed FAK and 
paxillin
In our cohort of patients FAK and paxillin transcript levels 
were assessed using qPCR (Figure 4). FAK and paxillin 
transcripts were higher in samples from patients who had 
died from the disease (versus living) though this did not 
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Figure 2a,b,c,d Paxillin immunofluorescence staining in ovarian cancer cells.
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Figure 3 Inhibition of ovarian cancer cell adhesion and migration. 
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cross the statistical significance threshold. FAK transcript 
copy numbers were significantly increased in patients 
who had cancer related incidence (tumour recurrence 
or metastasis) compared to those patients who were 
incidence free (p < 0.05) (Figure 4a). Increased paxillin 
transcript copies were also seen in patients with cancer 
related incidence (versus incidence free) however this did 
not reach statistical significance (Figure 4b). Ovarian cancer 
Figure 4 FAK and paxillin transcript levels in ovarian cancer tumours. 
tumours which were classified as highly differentiated, had 
significantly lower transcript numbers of FAK and paxillin 
compared to those that had been classified as moderately 
or poorly differentiated tumours (p < 0.05). Patients who 
were scored with high grade tumours (III and IV) also 
showed significantly increased transcript copies of FAK 
and paxillin compared to those patients who were scored 
with lower grade tumours (I and II)(p < 0.05).
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FAK transcript copies were increased in those patients who 
had died of the disease, and were significantly increased 
in patients with cancer related incidence (tumour 
recurrence and/or metastasis) compared with those who 
remained incidence free and those patients who had 
higher grade tumours (III and IV) compared to those with 
lower grade tumours (I and II) (p < 0.05) (a). Significantly 
lower transcript copies of FAK were seen in patients 
with highly differentiated tumours compared with those 
tumours which were moderately or poorly differentiated 
(p < 0.05). Paxillin transcript levels were also increased in 
patients who died of the disease (vs those who survived) 
and in those patients with cancer related incidence (vs 
those who were incidence free) though these increases 
did not reach a statistical significance (b). Significantly 
lower transcript copies of paxillin were seen in patients 
with highly differentiated tumours compared with those 
tumours which were moderately or poorly differentiated 
(p < 0.05). Significantly increased paxillin transcript levels 
were seen in patients with higher grade tumours (III and 
IV) compared to those with lower grade tumours (I and II) 
(p < 0.05).
Discussion
Ovarian cancer remains a major clinical problem as it is 
generally detected in the latter stages of the disease, when 
it is more difficult to treat, and metastasis is more likely to 
have occurred. The FAK and paxillin pathways have been 
heavily linked to the metastatic process of solid tumours. 
Results from our clinical cohort suggest that ovarian cancer 
is similar to other solid tumours, including breast and lung, 
in which increased transcript copy numbers of FAK and 
paxillin are linked to poor prognosis [23-28]. Our clinical 
cohort isolated those groups of patients who had poorly 
differentiated tumours, and those patients who died from 
the disease and/or had associated incidence.
 
The data from our study also provides insight into the 
mechanisms by which SLDM may exert some of its 
therapeutic effects in the treatment of cancer. Through the 
use of the protein array we were able to identify changes in 
FAK and paxillin. Of greater interest was the identification 
of some key phosphorylation sites which were affected 
after treatment with SLDM.
 
Tyrosine phosphorylation (397) of FAK occurs in response 
to a range of stimuli, including integrin clustering and 
growth factors, and has been identified as key to FAK’s 
intrinsic activity as well as providing a binding site for 
Src family kinases as well as other proteins [29, 30]. The 
decrease in autophosphorylation which was observed at 
FAK Y-397 is therefore of particular interest when taken 
into consideration with the observation by Tancioni 
et al. in which OPN, integrin β5 and FAK control ovarian 
cancer spheroid growth [31]. Grisaru-Granovsky et al. [32] 
identified that pY397 FAK and phosphorylated PAR1 were 
upregulated in ovarian cancer tissue and that possible 
interactions contributed to ovarian cancer [32]. Further 
research has shown that ovarian cancer cells metastasise 
as spheroid clusters in which FAK signalling functions and 
its downstream effectors support tumour cell survival [33, 
34]. 
Interestingly the phosphorylation of S-910 was also 
decreased, as seen from the antibody array data, 
suggesting that SLDM may exert its effects on FAK at more 
than one phosphorylation site and may potentially affect 
ERK [35]. The Kinexus data highlights that part of the 
actions observed with SLDM treatment are linked to key 
phosphorylation events in the FAK pathway in particular. 
The decreased autophosphorylation at the Y-397 site, 
given its links with integrin and growth factor interactions, 
is a key observation and this site has been the target of 
many FAK specific small inhibitors as well as combination 
therapies between the FAK small inhibitors and other 
treatment [8, 10].
 
SLDM has a significant impact on the behaviour of ovarian 
cancer cell adhesion and migration, though not cell growth 
[20, 21]. Treatment with SLDM resulted in a concentration 
dependent inhibition of ovarian cell adhesion and migration, 
this was further evident when added in combination with 
a FAK small inhibitor. The expression of FAK has been 
demonstrated in a number of tumour types and has been 
linked to the clinical outcome of the patients. This link was 
well demonstrated in a meta-analysis, including over four 
thousands patients with varying tumour types, in that high 
FAK expression was highly associated with the overall 
survival [36]. The study has shown that this link to survival 
was highly significant for gastric cancer, liver cancer, 
ovarian and endometrial cancers and glioma. Ward et 
al. have also previously demonstrated that targeting FAK 
inhibits tumour progression and improves survival of the 
patients with ovarian cancer [33].
In a previous study exploring the potential mechanism(s) 
of action by which SLDM, the novel TCM derivative of YZXJ, 
exerts its anticancer effects we have reported that GSK-3 is 
also affected in vitro, and that combining SLDM with a GSK-
3β targeted small inhibitor also synergistically decreased 
cellular migration. This multi-targeted effect therefore 
makes it difficult, at this initial stage, to isolate which of 
these pathways has the greater influence on reducing 
ovarian cancer cell migration in vitro. Furthermore, cellular 
migration is linked to other key cancer traits such as 
angiogenesis. YZXJ has demonstrated anti-angiogenic 
effects on a variety of solid cancer cell types in vitro 
however as yet this property has not been investigated 
with treatment of SLDM.
Though SLDM appears to affect both SKOV-3 and COV-
504 cell adhesion and migration, the way in which these 
effects are achieved may differ in the different cell lines. 
Immunofluorescence staining of paxillin in this study 
showed that the different cell lines exhibited differing 
localisation of paxillin in the untreated controls. This 
in itself is interesting given that ovarian cancer is a 
heterogenous disease and SKOV-3 is derived from an 
epithelial adenocarcinoma and COV-504 is derived from 
the pleural effusion of an epithelial serous carcinoma. 
Therefore further investigation is required using both cell 
lines to investigate the possibility that differing components 
of SLDM affect various pathways, potentially through 
FAK, unique to the differing ovarian cancer cell molecular 
characteristics.
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Beyond the scope of this study, future investigation is 
further required to analyse the effects SLDM may have 
on other cancer cell traits, such as cell invasion, and the 
potential pathways implicated both at an in vitro and in 
vivo level. Beyond this, further bio-chemical analysis could 
allow for isolation of the exact chemical components 
within the SLDM which exert these effects and explore if 
its’ anticancer effects are derived from a synergistic rather 
than single targeted approach.
Subsequent work is now needed to further understand 
how this medicine, through isolating the fundamental 
mechanisms of action, could benefit cancer patients, 
potentially through combination with chemotherapeutic 
agents, with further in vitro and in vivo studies.
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